Aspirin Dose Escalation for the Prevention of Recurrent Preterm Delivery Trial

PHASE3RecruitingINTERVENTIONAL
Enrollment

1,800

Participants

Timeline

Start Date

June 10, 2025

Primary Completion Date

October 31, 2028

Study Completion Date

February 28, 2029

Conditions
Preterm DeliveryObstetrical Complications
Interventions
DRUG

162mg Aspirin

"Two 81mg aspirin tablets in an over-encapsulated capsule filled with microcrystalline cellulose.~Study intervention will be packaged into bottles (35 capsules per bottle)."

DRUG

81mg Aspirin

"One 81mg aspirin tablet in an over-encapsulated capsule filled with microcrystalline cellulose.~Study intervention will be packaged into bottles (35 capsules per bottle)."

Trial Locations (14)

10032

RECRUITING

Columbia University, New York

15213

NOT_YET_RECRUITING

Magee Women's Hospital of UPMC, Pittsburgh

19104

RECRUITING

Hospital of the University of Pennsylvania, Philadelphia

27599

RECRUITING

University of North Carolina - Chapel Hill, Chapel Hill

27710

RECRUITING

Duke University, Durham

35233

RECRUITING

University of Alabama - Birmingham, Birmingham

43210

RECRUITING

Ohio State University, Columbus

44109

RECRUITING

Case Western Reserve University, Cleveland

60611

RECRUITING

Northwestern University, Chicago

77030

RECRUITING

Baylor College of Medicine, Houston

RECRUITING

University of Texas - Houston, Houston

84132

RECRUITING

University of Utah Medical Center, Salt Lake City

94143

RECRUITING

Regents of the University of California San Francisco, San Francisco

02905

RECRUITING

Brown University, Providence

All Listed Sponsors
collaborator

Columbia University

OTHER

collaborator

Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

NIH

lead

The George Washington University Biostatistics Center

OTHER